PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
Background: Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) is unclear. Aim: We conducted a literature analysis with the aim to evaluate the efficacy and safety profile of a combination with RT and PAR...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/21/5380 |
| _version_ | 1797512735690326016 |
|---|---|
| author | Amelia Barcellini Pierre Loap Kazutoshi Murata Riccardo Villa Youlia Kirova Noriyuki Okonogi Ester Orlandi |
| author_facet | Amelia Barcellini Pierre Loap Kazutoshi Murata Riccardo Villa Youlia Kirova Noriyuki Okonogi Ester Orlandi |
| author_sort | Amelia Barcellini |
| collection | DOAJ |
| description | Background: Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) is unclear. Aim: We conducted a literature analysis with the aim to evaluate the efficacy and safety profile of a combination with RT and PARP-I. Method: The key issues for the current review were expressed in two questions according to the Population, Intervention, Control, Outcome (PICO) criteria: 1. What is the outcome and 2. What is the toxicity in patients treated with a combination of PARP-I and RT for a newly diagnosed or recurrent tumors? Results: A total of 12 clinical studies met the inclusion criteria including seven single-arm dose-escalation phase I studies, two phase II (two- and three-arms controlled trials) trials, one parallel-arm phase I study, and two phase I/II studies published between 2015 and 2021. RT was performed with photon beams and several schedules according to the clinical situation. The acute toxicity ≥ grade 3 ranged between 25% and >96%, which was divided into hematological or non-hematological adverse events. Conclusions: despite the heterogeneity of the evaluated patient populations and tumor types, and the limited number of the studies, this review suggests that a combination approach is feasible even though the efficacy profile remains unclear. |
| first_indexed | 2024-03-10T06:05:53Z |
| format | Article |
| id | doaj.art-c236196a40cd44788e22d26676f07db4 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T06:05:53Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-c236196a40cd44788e22d26676f07db42023-11-22T20:34:26ZengMDPI AGCancers2072-66942021-10-011321538010.3390/cancers13215380PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?Amelia Barcellini0Pierre Loap1Kazutoshi Murata2Riccardo Villa3Youlia Kirova4Noriyuki Okonogi5Ester Orlandi6Radiation Oncology Clinical Department, National Center for Oncological Hadrontherapy (CNAO), 27100 Pavia, ItalyRadiation Oncology Clinical Department, National Center for Oncological Hadrontherapy (CNAO), 27100 Pavia, ItalyNational Institutes for Quantum and Radiological Science and Technology, QST Hospital, Chiba 263-0024, JapanRadiation Oncology Clinical Department, National Center for Oncological Hadrontherapy (CNAO), 27100 Pavia, ItalyDepartment of Radiation Oncology, Institut Curie, 75005 Paris, FranceNational Institutes for Quantum and Radiological Science and Technology, QST Hospital, Chiba 263-0024, JapanRadiation Oncology Clinical Department, National Center for Oncological Hadrontherapy (CNAO), 27100 Pavia, ItalyBackground: Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) is unclear. Aim: We conducted a literature analysis with the aim to evaluate the efficacy and safety profile of a combination with RT and PARP-I. Method: The key issues for the current review were expressed in two questions according to the Population, Intervention, Control, Outcome (PICO) criteria: 1. What is the outcome and 2. What is the toxicity in patients treated with a combination of PARP-I and RT for a newly diagnosed or recurrent tumors? Results: A total of 12 clinical studies met the inclusion criteria including seven single-arm dose-escalation phase I studies, two phase II (two- and three-arms controlled trials) trials, one parallel-arm phase I study, and two phase I/II studies published between 2015 and 2021. RT was performed with photon beams and several schedules according to the clinical situation. The acute toxicity ≥ grade 3 ranged between 25% and >96%, which was divided into hematological or non-hematological adverse events. Conclusions: despite the heterogeneity of the evaluated patient populations and tumor types, and the limited number of the studies, this review suggests that a combination approach is feasible even though the efficacy profile remains unclear.https://www.mdpi.com/2072-6694/13/21/5380BRCAPARP-IPoly-ADP ribose polymeraseradiotherapytoxicitysynthetic lethality |
| spellingShingle | Amelia Barcellini Pierre Loap Kazutoshi Murata Riccardo Villa Youlia Kirova Noriyuki Okonogi Ester Orlandi PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do? Cancers BRCA PARP-I Poly-ADP ribose polymerase radiotherapy toxicity synthetic lethality |
| title | PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do? |
| title_full | PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do? |
| title_fullStr | PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do? |
| title_full_unstemmed | PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do? |
| title_short | PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do? |
| title_sort | parp inhibitors in combination with radiotherapy to do or not to do |
| topic | BRCA PARP-I Poly-ADP ribose polymerase radiotherapy toxicity synthetic lethality |
| url | https://www.mdpi.com/2072-6694/13/21/5380 |
| work_keys_str_mv | AT ameliabarcellini parpinhibitorsincombinationwithradiotherapytodoornottodo AT pierreloap parpinhibitorsincombinationwithradiotherapytodoornottodo AT kazutoshimurata parpinhibitorsincombinationwithradiotherapytodoornottodo AT riccardovilla parpinhibitorsincombinationwithradiotherapytodoornottodo AT youliakirova parpinhibitorsincombinationwithradiotherapytodoornottodo AT noriyukiokonogi parpinhibitorsincombinationwithradiotherapytodoornottodo AT esterorlandi parpinhibitorsincombinationwithradiotherapytodoornottodo |